1. Home
  2. ECOR vs GANX Comparison

ECOR vs GANX Comparison

Compare ECOR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECOR
  • GANX
  • Stock Information
  • Founded
  • ECOR 2005
  • GANX 2017
  • Country
  • ECOR United States
  • GANX United States
  • Employees
  • ECOR N/A
  • GANX N/A
  • Industry
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ECOR Health Care
  • GANX Health Care
  • Exchange
  • ECOR Nasdaq
  • GANX Nasdaq
  • Market Cap
  • ECOR 50.1M
  • GANX 57.9M
  • IPO Year
  • ECOR 2018
  • GANX 2021
  • Fundamental
  • Price
  • ECOR $5.04
  • GANX $1.89
  • Analyst Decision
  • ECOR Strong Buy
  • GANX Strong Buy
  • Analyst Count
  • ECOR 2
  • GANX 5
  • Target Price
  • ECOR $25.50
  • GANX $8.20
  • AVG Volume (30 Days)
  • ECOR 182.1K
  • GANX 226.2K
  • Earning Date
  • ECOR 05-07-2025
  • GANX 05-14-2025
  • Dividend Yield
  • ECOR N/A
  • GANX N/A
  • EPS Growth
  • ECOR N/A
  • GANX N/A
  • EPS
  • ECOR N/A
  • GANX N/A
  • Revenue
  • ECOR $26,458,000.00
  • GANX N/A
  • Revenue This Year
  • ECOR $26.76
  • GANX N/A
  • Revenue Next Year
  • ECOR $44.87
  • GANX N/A
  • P/E Ratio
  • ECOR N/A
  • GANX N/A
  • Revenue Growth
  • ECOR 41.54
  • GANX N/A
  • 52 Week Low
  • ECOR $4.47
  • GANX $0.89
  • 52 Week High
  • ECOR $19.49
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • ECOR 39.64
  • GANX 45.23
  • Support Level
  • ECOR $4.77
  • GANX $1.80
  • Resistance Level
  • ECOR $5.49
  • GANX $1.85
  • Average True Range (ATR)
  • ECOR 0.44
  • GANX 0.12
  • MACD
  • ECOR 0.08
  • GANX -0.01
  • Stochastic Oscillator
  • ECOR 41.08
  • GANX 20.00

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: